Last reviewed · How we verify
SOMATREM
Somatrem is a marketed drug with a key composition patent expiring in 2028, positioning it as an established player in its therapeutic area. The drug's primary strength lies in its current market presence, leveraging its approved status and ongoing revenue generation. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics and biosimilars.
At a glance
| Generic name | SOMATREM |
|---|---|
| Modality | Recombinant protein |
| Phase | FDA-approved |
| First approval | 1985 |
Approved indications
Common side effects
Key clinical trials
- National Cooperative Growth Study in CKD
- National Cooperative Growth Study (NCGS): A Post-marketing Surveillance Program for Nutropin, Nutropin AQ, Nutropin Depot, and Protropin
- Bone Mineral Density (BMD) in Adolescents With Growth Hormone Deficiency (GHD)
- A Study in Children With Growth Failure Due to Chronic Renal Insufficiency (CRI) or End Stage Renal Disease (ESRD)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SOMATREM CI brief — competitive landscape report
- SOMATREM updates RSS · CI watch RSS